S
Supernus Pharmaceuticals
Specialty pharmaceutical firm commercializing central nervous system treatments
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company was founded in 2005 by Jack A. Khattar, who serves as the President and CEO. It was established as a spin-off from Shire Laboratories, the drug delivery subsidiary of Shire plc, where Mr. Khattar had also held the position of President and CEO. His career includes extensive experience in marketing, business development, and corporate strategy at pharmaceutical and drug delivery companies such as Merck & Co., Novartis, and CIMA Labs.
The company's business model is fully integrated, covering research and development, manufacturing, and commercialization. Revenue is primarily generated from product sales, alongside licensing agreements and partnerships. Supernus focuses its marketing and sales efforts within the United States, utilizing its own specialty sales force to target neurologists and psychiatrists. For international markets, the company pursues strategic collaborations with other pharmaceutical firms to license its products. The company's portfolio includes treatments for conditions such as epilepsy, migraine, Parkinson's disease (PD), and attention-deficit hyperactivity disorder (ADHD). Key products include Qelbree, Gocovri, Oxtellar XR, and Trokendi XR. Supernus has expanded its portfolio through strategic acquisitions, including the CNS portfolio of US WorldMeds in 2020 and Sage Therapeutics in 2025, which added ZURZUVAE for postpartum depression.
Supernus is a publicly traded company headquartered in Rockville, Maryland. The company invests significantly in research and development to create new treatments for CNS disorders, with a pipeline that includes candidates for depression and other neurological conditions. It leverages proprietary drug delivery technologies, such as Microtrol, Solutrol, and EnSoTrol, to improve upon existing medications through advanced extended-release formulations.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2005
- Headquarters
- Rockville, United States
- Listing
- IPO 2012
- Employees
- 842
- Open positions
- 23
- Dealroom signal
- 77.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Neurology, Mental Health, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 4 companies, latest Aug 2026
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| MERGEROther financing | Aug 2026 | $0 | — | Indivior | ↗ |
| POST IPO DEBTDebt | Feb 2023 | $150M | — | UBS | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $867M | +20.6% | $157M | 18.1% |
| 2025 | $719M | +8.6% | $68M | 9.5% |
| 2024 | $662M | +8.9% | $172M | 26% |
| 2023 | $608M | -8.9% | $109M | 17.9% |
| 2022 | $667M | +15.1% | $150M | 22.5% |
| 2021 | $580M | +11.4% | $120M | 20.7% |
| 2020 | $520M | — | $210M | 40.4% |
Growth signals
Latest recorded traffic for Supernus Pharmaceuticals is 21K monthly website visits, up 40% over the last three months. Supernus Pharmaceuticals's team grew 32% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
IndiviorBon Air, United StatesA global pharmaceutical company working to help change patients’ lives by pioneering life-transforming treatment for addiction and other serious mental illnesses
$4.1Bvaluation
SAGE TherapeuticsRaleigh, United StatesDevelops and delivers novel medicines for most debilitating and disabling central nervous system disorders
$191Mvaluation
Adamas PharmaceuticalsEmeryville, United StatesCreate and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology
$400Mvaluation
Biscayne NeuroTherapeuticsMiami, United StatesBiscayne Pharmaceuticals discovers and develops novel therapies based on growth hormone-releasing hormone (GHRH) analogs
$185Mvaluation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Supernus Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Supernus Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.